The Zhitong Finance App learned that Citibank released a research report saying that the bank held an expert meeting with key SANOVO researchers on November 5 to further strengthen the positive view on the potential of savolitinib for EGFR mutant non-small cell lung cancer after first-line and osimertinib treatment, maintain a “buy/high risk” rating, and listed Hewong Pharmaceutical (00013.HK) as the new preferred stock. The target price was raised from HK$40.1 to HK$43.2.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.